190 related articles for article (PubMed ID: 34405703)
1.
Groussin L; Bessiene L; Arrondeau J; Garinet S; Cochand-Priollet B; Lupo A; Zerbit J; Clerc J; Huillard O
Thyroid; 2021 Oct; 31(10):1603-1604. PubMed ID: 34405703
[No Abstract] [Full Text] [Related]
2. NTRK and RET fusion-directed therapy in pediatric thyroid cancer yields a tumor response and radioiodine uptake.
Lee YA; Lee H; Im SW; Song YS; Oh DY; Kang HJ; Won JK; Jung KC; Kwon D; Chung EJ; Hah JH; Paeng JC; Kim JH; Choi J; Kim OH; Oh JM; Ahn BC; Wirth LJ; Shin CH; Kim JI; Park YJ
J Clin Invest; 2021 Sep; 131(18):. PubMed ID: 34237031
[TBL] [Abstract][Full Text] [Related]
3. Sustained Response with Dose-reduced Selpercatinib in a Pediatric Patient with Metastatic NCOA4-RET Fusion Papillary Thyroid Carcinoma.
Suydam AC; Bach A; Markovina S; Grigsby P; Sprague J; Armstrong AE
J Pediatr Hematol Oncol; 2023 Nov; 45(8):e984-e987. PubMed ID: 37565829
[TBL] [Abstract][Full Text] [Related]
4. Detection of RET rearrangements in papillary thyroid carcinoma using RT-PCR and FISH techniques - A molecular and clinical analysis.
Musholt TJ; Staubitz JI; Antonio Cámara RJ; Musholt PB; Humberg D; Springer E; Schad A
Eur J Surg Oncol; 2019 Jun; 45(6):1018-1024. PubMed ID: 30472213
[TBL] [Abstract][Full Text] [Related]
5. Successful combination of selpercatinib and radioiodine after pretherapeutic dose estimation in RET-altered thyroid carcinoma.
Werner RA; Sayehli C; Hänscheid H; Higuchi T; Serfling SE; Fassnacht M; Goebeler ME; Buck AK; Kroiss M
Eur J Nucl Med Mol Imaging; 2023 May; 50(6):1833-1834. PubMed ID: 36522435
[No Abstract] [Full Text] [Related]
6. Selpercatinib.
Am J Health Syst Pharm; 2020 Oct; 77(22):1818-1821. PubMed ID: 32930710
[No Abstract] [Full Text] [Related]
7. GADD45B Transcript Is a Prognostic Marker in Papillary Thyroid Carcinoma Patients Treated With Total Thyroidectomy and Radioiodine Therapy.
Barros-Filho MC; de Mello JBH; Marchi FA; Pinto CAL; da Silva IC; Damasceno PKF; Soares MBP; Kowalski LP; Rogatto SR
Front Endocrinol (Lausanne); 2020; 11():269. PubMed ID: 32425887
[TBL] [Abstract][Full Text] [Related]
8. [Drug approval: Selpercatinib and pralsetinib - RET-altered thyroid cancer].
Courtier B; Hadoux J
Bull Cancer; 2021 Nov; 108(11):989-991. PubMed ID: 34598787
[No Abstract] [Full Text] [Related]
9. Pralsetinib: First Approval.
Markham A
Drugs; 2020 Nov; 80(17):1865-1870. PubMed ID: 33136236
[TBL] [Abstract][Full Text] [Related]
10.
Pekova B; Sykorova V; Dvorakova S; Vaclavikova E; Moravcova J; Katra R; Astl J; Vlcek P; Kodetova D; Vcelak J; Bendlova B
Thyroid; 2020 Dec; 30(12):1771-1780. PubMed ID: 32495721
[No Abstract] [Full Text] [Related]
11. KIF5B/RET Rearrangement in a Carcinoma of the Thyroid Gland: A Case Report of a Fatal Disease.
Viola D; Giani C; Mazzeo S; Ugolini C; Ciampi R; Molinaro E; Agate L; Borrelli N; Chella A; Fontanini G; Basolo F; Elisei R
J Clin Endocrinol Metab; 2017 Sep; 102(9):3091-3096. PubMed ID: 28911147
[TBL] [Abstract][Full Text] [Related]
12. RET/PTC Gene Rearrangements in Thyroid Carcinogenesis: Assessment and Clinico-Pathological Correlations.
Khan MS; Qadri Q; Makhdoomi MJ; Wani MA; Malik AA; Niyaz M; Masoodi SR; Andrabi KI; Ahmad R; Mudassar S
Pathol Oncol Res; 2020 Jan; 26(1):507-513. PubMed ID: 30467698
[TBL] [Abstract][Full Text] [Related]
13. Papillary Thyroid Cancer: Genetic Alterations and Molecular Biomarker Investigations.
Abdullah MI; Junit SM; Ng KL; Jayapalan JJ; Karikalan B; Hashim OH
Int J Med Sci; 2019; 16(3):450-460. PubMed ID: 30911279
[TBL] [Abstract][Full Text] [Related]
14. A molecular approach combined with American Thyroid Association classification better stratifies recurrence risk of classic histology papillary thyroid cancer.
Lin AJ; Samson P; DeWees T; Henke L; Baranski T; Schwarz J; Pfeifer J; Grigsby P; Markovina S
Cancer Med; 2019 Jan; 8(1):437-446. PubMed ID: 30552739
[TBL] [Abstract][Full Text] [Related]
15. Novel rearrangements involving the RET gene in papillary thyroid carcinoma.
Staubitz JI; Schad A; Springer E; Rajalingam K; Lang H; Roth W; Hartmann N; Musholt TJ
Cancer Genet; 2019 Jan; 230():13-20. PubMed ID: 30466862
[TBL] [Abstract][Full Text] [Related]
16. Selpercatinib: First Approval.
Markham A
Drugs; 2020 Jul; 80(11):1119-1124. PubMed ID: 32557397
[TBL] [Abstract][Full Text] [Related]
17. Larotrectinib-Enhanced Radioactive Iodine Uptake in Advanced Thyroid Cancer.
Groussin L; Clerc J; Huillard O
N Engl J Med; 2020 Oct; 383(17):1686-1687. PubMed ID: 33085869
[No Abstract] [Full Text] [Related]
18. Rearranged-in-transfection inhibitors: emerging agnostic targeted therapies for solid tumors.
Saleh K; Felefly T; Khalife N; Kourie HR
Pharmacogenomics; 2021 Apr; 22(5):247-250. PubMed ID: 33754802
[No Abstract] [Full Text] [Related]
19. Precision Targeted Therapy with BLU-667 for
Subbiah V; Gainor JF; Rahal R; Brubaker JD; Kim JL; Maynard M; Hu W; Cao Q; Sheets MP; Wilson D; Wilson KJ; DiPietro L; Fleming P; Palmer M; Hu MI; Wirth L; Brose MS; Ou SI; Taylor M; Garralda E; Miller S; Wolf B; Lengauer C; Guzi T; Evans EK
Cancer Discov; 2018 Jul; 8(7):836-849. PubMed ID: 29657135
[TBL] [Abstract][Full Text] [Related]
20. Recurrence predictability by various staging systems in 283 patients after thyroidectomy and radioactive iodine treated for papillary thyroid carcinoma.
Yaniv D; Mizrachi A; Raz R; Tzelnick S; Feinmesser R; Hamzany Y; Vaisbuch Y; Hilly O
Clin Otolaryngol; 2019 Nov; 44(6):1147-1152. PubMed ID: 31437357
[No Abstract] [Full Text] [Related]
[Next] [New Search]
